USCWA
RETA

U.S. Capital Wealth Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-300
Closed -$11.4K – 1601
2022
Q4 		$11.4K Buy
+300
New +$10.3K ﹤0.01% 1245

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

U.S. Capital Wealth Advisors's RETA Position: Q1 2023 in Review

U.S. Capital Wealth Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2023, closing a stake of 300 shares — an estimated $11.4K sold.

U.S. Capital Wealth Advisors first reported a position in RETA in Q4 2022 and held it in 1 quarter. The position peaked at $11.4K in Q4 2022. 205 funds tracked by Wall St. Rank hold RETA as of Q1 2023.

  • U.S. Capital Wealth Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
  • U.S. Capital Wealth Advisors sold 300 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2023, an estimated $11.4K.
  • U.S. Capital Wealth Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2022 and held it in 1 quarter.
  • U.S. Capital Wealth Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $11.4K in Q4 2022.
  • 205 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2023.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2023, filed 11 May 2023.